We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.18%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.32B
AUM Growth
+$87.8M
Cap. Flow
+$6.46M
Cap. Flow %
0.49%
Top 10 Hldgs %
27.55%
Holding
138
New
17
Increased
50
Reduced
27
Closed
18

Top Buys

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$28.2M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$22.2M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$17.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$17.5M
5
AGN
Allergan plc
AGN
+$10.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$38M
2
STJ
St Jude Medical
STJ
+$33.4M
3
TMH
Team Health Holdings Inc
TMH
+$17M
4
ADPT
Adeptus Health Inc
ADPT
+$14.4M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Financials 3.37%
3 Industrials 0.48%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
51
Vertex Pharmaceuticals
VRTX
$126B
$9.15M 0.69%
72,750
+500
+0.7% +$60.4K
ANAC
52
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$8.7M 0.66%
77,000
-9,000
-10% -$991K
JUNO
53
DELISTED
Juno Therapeutics, Inc.
JUNO
$8.66M 0.66%
197,001
– –
MCRB icon
54
Seres Therapeutics
MCRB
$48.4M
$8.61M 0.65%
12,270
+3,270
+36% +$2.15M
BHC icon
55
Bausch Health
BHC
$2.34B
$8.51M 0.64%
83,700
-28,800
-26% -$3.24M
PTLA
56
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.49M 0.64%
+165,000
New +$8M
INOV
57
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$8.11M 0.61%
477,300
-207,700
-30% -$4.13M
HTWR
58
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$8.1M 0.61%
160,669
-112,331
-41% -$5.28M
GWPH
59
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.05M 0.61%
116,000
+30,500
+36% +$2.48M
INSM icon
60
Insmed
INSM
$28.6B
$7.85M 0.59%
432,500
+67,500
+18% +$1.19M
XENT
61
DELISTED
Intersect ENT, Inc
XENT
$7.59M 0.58%
337,293
+99,793
+42% +$1.97M
SRGA
62
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$7.38M 0.56%
62,000
– –
BMRN icon
63
BioMarin Pharmaceuticals
BMRN
$12.4B
$7.33M 0.56%
70,000
+19,500
+39% +$2.04M
RLYP
64
DELISTED
RELYPSA INC COM
RLYP
$7.14M 0.54%
252,000
– –
NVDQ
65
DELISTED
Novadaq Technologies Inc.
NVDQ
$6.88M 0.52%
540,000
– –
EHC icon
66
Encompass Health
EHC
$12.4B
$6.79M 0.51%
245,115
-179,123
-42% -$5.1M
MGNX icon
67
MacroGenics
MGNX
$257M
$6.75M 0.51%
218,000
– –
TNDM icon
68
Tandem Diabetes Care
TNDM
$1.56B
$6.64M 0.5%
56,250
+2,000
+4% +$198K
CHRS icon
69
Coherus Oncology
CHRS
$196M
$6.47M 0.49%
282,000
-3,000
-1% -$77.2K
NVAX icon
70
Novavax
NVAX
$1.31B
$6.46M 0.49%
38,500
+2,750
+8% +$423K
EVHC
71
DELISTED
Envision Healthcare Holdings Inc
EVHC
$6.36M 0.48%
81,830
-108,550
-57% -$9.38M
ATHN
72
DELISTED
Athenahealth, Inc.
ATHN
$6.36M 0.48%
39,500
+1,500
+4% +$232K
XNPT
73
DELISTED
XENOPORT, INC.
XNPT
$6.04M 0.46%
1,100,000
+545,000
+98% +$3.06M
REGN icon
74
Regeneron Pharmaceuticals
REGN
$80.8B
$5.97M 0.45%
11,000
– –
EPZM
75
DELISTED
Epizyme, Inc
EPZM
$5.93M 0.45%
370,000
+60,000
+19% +$890K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rock Springs Capital Management held 138 positions worth $1.32B, up 7.1% from $1.23B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q4 2015 filing shows 17 new, 50 increased, 27 reduced and 18 closed positions. Its largest new stake was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M. The largest sale was AbbVie, an estimated $38M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 76% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2015 buy was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M.
  • Rock Springs Capital Management added most to Allergan plc in Q4 2015, an estimated $10.7M increase.
  • Rock Springs Capital Management's biggest Q4 2015 reduction was AbbVie, cutting an estimated $38M.
  • Rock Springs Capital Management fully exited St Jude Medical in Q4 2015, selling an estimated $33.4M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.32B portfolio in Q4 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 18 in Q4 2015.
  • Rock Springs Capital Management's portfolio value rose 7.1% quarter-over-quarter to $1.32B.

Based on Rock Springs Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.